Direct oral anticoagulants in patients with hematologic malignancies.
Administration, Oral
Adult
Aged
Aged, 80 and over
Anticoagulants
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Atrial Fibrillation
/ chemically induced
Female
Follow-Up Studies
Hematologic Neoplasms
/ drug therapy
Hemorrhage
/ chemically induced
Humans
Male
Middle Aged
Prognosis
Retrospective Studies
Venous Thromboembolism
/ chemically induced
atrial fibrillation
direct oral anticoagulants
haematologic malignancies
venous thromboembolism
Journal
Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
20
04
2020
revised:
08
06
2020
accepted:
12
06
2020
pubmed:
27
6
2020
medline:
3
11
2020
entrez:
27
6
2020
Statut:
ppublish
Résumé
The anticoagulant treatment for patients with hematologic malignancies is low molecular weight heparin (LMWH), which is considered the safest in this particular patients setting. Although direct oral anticoagulants (DOACs) have proven their efficacy and safety in patients with cancer, their use can be challenging in patients with hematologic malignancies due to the peculiarity of these neoplasms: high thrombotic risk, possible onset of thrombocytopenia and concomitant anticancer therapies. The aim of our study was to evaluate the efficacy and safety of DOACs for venous thromboembolism or atrial fibrillation in patients with hematologic malignancies and plasmatic DOACs level during anticancer therapy and at time of bleeding or thrombotic complications. We evaluated patients with hematologic malignancies treated with DOACs for venous thromboembolism or atrial fibrillation-therapy was maintained until the platelet count was ≥50 × 10
Substances chimiques
Anticoagulants
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
589-596Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
De Stefano V, Sora F, Rossi E, et al. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost. 2005;3:1985-1992.
Grace RF, Dahlberg SE, Neuberg D, et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011;152:452-459.
Yokoyama K, Murata M, Ikeda Y, Okamoto S. Incidence and risk factors for developing venous thromboembolism in Japanese with diffuse large b-cell lymphoma. Thromb Res. 2012;130:7-11.
Kristinsson SY, Fears TR, Gridley G, et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood. 2008;112:3582-3586.
Carrier M, Le Gal G, Tay J, Wu C, Lee AY. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost. 2011;9:653-663.
Caruso V, Iacoviello L, Di Castelnuovo A, Storti S, Donati MB. Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukemia: results from a meta-analysis. J Thromb Haemost. 2007;5:621-623.
Ku GH, White RH, Chew HK, Harvey DJ, Zhou H, Wun T. Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. Blood. 2009;113:3911-3917.
Whittle AM, Allsup DJ, Bailey JR. Chronic lymphocytic leukaemia is a risk factor for venous thromboembolism. Leuk Res. 2011;35:419-421.
Rungjirajittranon T, Owattanapanich W, Ungprasert P, Siritanaratkul N, Ruchutrakool T. A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms. BMC Cancer. 2019;19:184.
Mitchell LG, Sutor AH, Andrew M. Hemostasis in childhood acute lymphoblastic leukemia: coagulopathy induced by disease and treatment. Semin Thromb Hemost. 1995;21:390-401.
Couturier MA, Huguet F, Chevallier P, et al. Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: the GRAALL experience. Am J Hematol. 2015;90:986-991.
Breccia M, Avvisati G, Latagliata R, et al. Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features. Leukemia. 2006;21:79-83.
Nadir Y, Katz T, Sarig G, et al. Hemostatic balance on the surface of leukemic cells: the role of tissue factor and urokinase plasminogen activator receptor. Haematologica. 2005;90:1549-1556.
Kekre N, Connors JM. Venous thromboembolism incidence in hematologic malignancies. Blood Rev. 2019 Jan;33:24-32.
Hunault-Berger M, Chevallier P, Delain M, et al. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study. Haematologica. 2008;93:1488-1494.
Campbell PM, Ippoliti C, Parmar S. Safety of anticoagulation in thrombocytopenic patients with hematologic malignancies: a case series. J Oncol Pharm Pract. 2017;23:220-225.
Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C, Dogne JM. Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis. JAMA Oncol. 2016;2:625-632.
Mahé K, Delluc A, Chauveau A, et al. Incidence and impact of atrial arrhythmias on thrombotic events in MPNs. Ann Hematol. 2018;97(1):101-107.
Alvarez-Larrán A. Atrial fibrillation and MPNs. Ann Hematol. 2018;97(4):743.
Leong DP, Caron F, Hillis C, et al. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 2016;128(1):138-140.
Kopolovic I, Lee AY, Wu C. Management and outcomes of cancer-associated venous thromboembolism in patients with concomitant thrombocytopenia: a retrospective cohort study. Ann Hematol. 2015;94:329-336.
Lee AYY, Levine MN, Baker RI, et al. Low-molecular weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146-153.
Khorana AA, Noble S, Lee AYY, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost. 2018;16(9):1891-1894.
Wang TF, Zwicker JI, Ay C, et al. The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2019;17(10):1772-1778.
Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2017;378:615-624.
Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36:2017-2023.
Drug Interactions & Labeling. Drug development and drug interactions: table of substrates, inhibitors and inducers, http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm. Aaccessed December 10, 2018.
Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315-352.
Steffel J, Verhamme P, Potpara TS, et al. The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace. 2018;20(8):1231-1242.
Kaatz S, Ahmad D, Spyropoulos AC, Schulman S, Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(11):2119-2126.
Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-694.
Samuelson BT, Cuker A, Siegal DM, Crowther M, Garcia DA. Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review. Chest. 2016;151(1):127-138.
Simkovic M, Vodarek P, Motyckova M, et al. Venous thromboembolism in patients with chronic lymphocytic leukemia. Thromb Res. 2015;136:1082-1086.
Ganatra S, Sharma A, Shah S, et al. Ibrutinib-associated atrial fibrillation. JACC Clin Electrophysiol. 2018;4(12):1491-1500.
Thorp BC, Badoux X. Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management. Leuk Lymphoma. 2018;59(2):311-320.
Santi RM, Ceccarelli M, Catania G, et al. PO-03-Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in non Hodgkin lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL). Thromb Res. 2016;140(Suppl 1):S177.
Zhou X, Teegala S, Huen A, et al. Incidence and risk factors of venous thromboembolic events in lymphoma. Am J Med. 2010;123:935-941.
Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013;122(13):2176-2184.
De Stefano V, Vannucchi AM, Ruggeri M, et al. Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients. Blood Cancer J. 2016;6(11):e493. https://doi.org/10.1038/bcj.2016.103.
Rickles FR, Falanga A, Montesinos P, Sanz MA, Brenner B, Barbui T. Bleeding and thrombosis in acute leukemia: what does the future of therapy look like? Thromb Res. 2007;120(Suppl 2):S99-S106.
Pamphilon DH, Aparicio SR, Roberts BE, Menys VC, Tate G, Davies JA. The myelodysplastic syndromes-a study of haemostatic function and platelet ultrastructure. Scand J Haematol. 1984;33(5):486-491.
Glaspy JA. Hemostatic abnormalities in multiple myeloma and related disorders. Hematol Oncol Clin North Am. 1992;6(6):1301-1314.
Konkle BA. Acquired disorders of platelet function. Hematology Am Soc Hematol Educ Program. 2011;2011:391-396.
Annibali O, Napolitano M, Avvisati G, Siragusa S. Incidence of venous thromboembolism and use of anticoagulation in hematological malignancies: critical review of the literature. Crit Rev Oncol Hematol. 2018;124:41-50.
Kim S, Namba J, Goodman AM, Nguyen T, Saunders IM. Safety and efficacy of direct oral anticoagulants for venous thromboembolism and stroke prophylaxis in patients with hematologic malignancies. J Oncol Pharm Pract. 2020;26(2):351-360.
Sorigue M, Cañamero E, Siguenza P, Nomdedeu M, López-Núñez JJ. Recent developments and persisting challenges in the prevention and treatment of venous thromboembolism in patients with hematological malignancies. Leuk Lymphoma. 2020;61(6):1-15.
Ravikumar R, Lim CS, Davies AH. The role of new oral anticoagulants (NOACs) in cancer patients. Adv Exp Med Biol. 2017;906(2):137-148.
Ianotto JC, Couturier MA, Galinat H, et al. Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms. Int J Hematol. 2017;106(4):517-521.
Curto-Garcia N, Doyle AJ, Breen KA, et al. Outcomes of patients receiving direct oral anticoagulants for myeloproliferative neoplasm-associated venous thromboembolism in a large tertiary centre in the UK. Br J Haematol. 2020;189(3):e79-e81.
Rhea IB, Lyon AR, Fradley MG. Anticoagulation of cardiovascular conditions in the cancer patient: review of old and new therapies. Curr Oncol Rep. 2019;21(5):45.
Hellwig T, Gulseth M. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation? Ann Pharmacother. 2013;47:1478-1487.
Forbes HL, Polasek TM. Potential drug-drug interactions with direct oral anticoagulants in elderly hospitalized patients. Ther Adv Drug Saf. 2017;8:319-328.